Kristian Reich

发表

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.

J. Silverberg, A. Blauvelt, April W. Armstrong, 2023, American journal of clinical dermatology.

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate‐to‐severe plaque psoriasis

A. Armstrong, K. Reich, A. Blauvelt, 2017, The British journal of dermatology.

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

A. Gottlieb, M. Lebwohl, K. Reich, 2020, The British journal of dermatology.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

A. Menter, E. Edson-Heredia, K. Reich, 2019, The British journal of dermatology.

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

M. Gooderham, K. Papp, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

S. Green, M. Gooderham, K. Papp, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

A. Kimball, S. Green, M. Gooderham, 2018, The British journal of dermatology.

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

Y. Wang, U. Mrowietz, Kristian Reich, 2013, The British journal of dermatology.

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

M. Gooderham, A. Bewley, K. Reich, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial

F. Nestle, J. Ortonne, K. Papp, 2006, The British journal of dermatology.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

F. Vanaclocha, K. Reich, A. Blauvelt, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2)

K. Reich, J. Barker, G. Wozel, 2013, The British journal of dermatology.

One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis

S. Chimenti, J. Lambert, T. Luger, 2014, The British journal of dermatology.

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

M. Lebwohl, K. Reich, R. Warren, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.